The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
News|Articles|March 6, 2024
SLIDESHOW: Events in Conjunction With the 2024 AAD Meeting
Author(s)Lauren Buchanan, MA, Managing Editor
There are several events in conjunction with AAD featuring opportunities for dermatology clinicians to gain CME credit, network, explore career options, and gain pearls to put into practice.
Advertisement
Are you attending AAD or any of these events? We would love to connect! Email
Advertisement
Related to this article
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
ORKA-001 Achieves 61% Complete Skin Clearance in Psoriasis
2
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
3
Avoiding Common Mistakes When Escalating Therapy in Psoriasis
4
FDA Revises TB Evaluation Guidance for SKYRIZI
5